MCID: CNS004
MIFTS: 56

Constipation

Categories: Gastrointestinal diseases

Aliases & Classifications for Constipation

MalaCards integrated aliases for Constipation:

Name: Constipation 12 29 6 43 44 15

Classifications:



Summaries for Constipation

MedlinePlus : 43 Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious. There are many things you can do to prevent constipation. They include Eating more fruits, vegetables and grains, which are high in fiber Drinking plenty of water and other liquids Getting enough exercise Taking time to have a bowel movement when you need to Using laxatives only if your doctor says you should Asking your doctor if medicines you take may cause constipation It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Constipation is related to hypoganglionosis and hirschsprung disease 1. An important gene associated with Constipation is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Naloxone and Oxycodone have been mentioned in the context of this disorder. Affiliated tissues include lung, colon and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces.

Wikipedia : 76 Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and... more...

Related Diseases for Constipation

Diseases related to Constipation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 hypoganglionosis 32.8 GDNF RET
2 hirschsprung disease 1 32.8 EDNRB GDNF RET VIP
3 intestinal pseudo-obstruction 32.6 EDNRB FLNA RET SST
4 intestinal obstruction 32.3 EDNRB FLNA GDNF MLN RET
5 central hypoventilation syndrome, congenital 32.1 EDNRB GDNF RET
6 irritable bowel syndrome 31.5 CCK HTR3A HTR4 MLN SLC6A4 TAC1
7 megacolon 31.3 EDNRB GDNF RET VIP
8 gastroesophageal reflux 30.6 CCK MLN PYY VIP
9 functional diarrhea 30.5 HTR3A HTR4 TAC1
10 carcinoid syndrome 30.5 HTR3A PYY SST
11 anismus 30.5 TAC1 VIP
12 diarrhea 30.2 CCK HTR3A SST
13 gastroparesis 30.0 CCK HTR3A MLN MLNR
14 dyspepsia 30.0 CCK HTR3A SLC6A4 SST
15 colonic pseudo-obstruction 29.8 HTR4 KIT MLN MLNR SST
16 gastrointestinal system disease 29.6 CCK EDNRB HTR4 MLN PYY SST
17 outlet dysfunction constipation 12.1
18 coarse face hypotonia constipation 11.9
19 fecal incontinence 11.2
20 opitz-kaveggia syndrome 11.2
21 pitt-hopkins syndrome 11.2
22 porphyria 11.2
23 parkinson disease, late-onset 11.1
24 sacral defect with anterior meningocele 11.1
25 medullary sponge kidney 11.0 GDNF RET
26 colorectal cancer 11.0
27 porphyria, acute hepatic 11.0
28 primary hyperparathyroidism 11.0
29 hemorrhoid 11.0
30 celiac disease 1 11.0
31 adrenomyodystrophy 11.0
32 beriberi 11.0
33 peritonitis 11.0
34 disseminated peritoneal leiomyomatosis 11.0
35 ulcerative proctitis 11.0
36 wdha syndrome 10.9 SST VIP
37 multiple endocrine neoplasia, type iib 10.9 EDNRB GDNF RET
38 goldberg-shprintzen syndrome 10.9 EDNRB GDNF RET
39 colonic disease 10.9 EDNRB GDNF RET
40 waardenburg syndrome, type 4a 10.8 EDNRB RET
41 pylorospasm 10.8 HTR4 MLN SST
42 postgastrectomy syndrome 10.8 PYY SST VIP
43 pyloric stenosis 10.8 GDNF RET SST
44 hashimoto thyroiditis 10.8
45 urofacial syndrome 1 10.8
46 fg syndrome 2 10.8
47 fg syndrome 4 10.8
48 neuropathy, hereditary sensory and autonomic, type vii 10.8
49 tarlov cysts 10.8
50 achalasia 10.7 KIT RET VIP

Graphical network of the top 20 diseases related to Constipation:



Diseases related to Constipation

Symptoms & Phenotypes for Constipation

GenomeRNAi Phenotypes related to Constipation according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.77 HTR3A MLN SLC6A4 EDNRB HTR4 MLNR
2 Decreased viability GR00381-A-3 9.77 SLC6A4 HTR3A MLN
3 Decreased viability GR00402-S-2 9.77 HTR3A MLN SLC6A4 EDNRB HTR4 MLNR

MGI Mouse Phenotypes related to Constipation:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 AQP3 CCK CLCN2 EDNRB FLNA GDNF
2 homeostasis/metabolism MP:0005376 10.31 PPOX PYY RET SLC6A4 SST VIP
3 growth/size/body region MP:0005378 10.21 AQP3 EDNRB FLNA GDNF HTR3A HTR4
4 cardiovascular system MP:0005385 10.19 AQP3 CLCN2 EDNRB FLNA GDNF KIT
5 digestive/alimentary MP:0005381 10.18 AQP3 CLCN2 EDNRB FLNA GDNF KIT
6 mortality/aging MP:0010768 10.17 AQP3 EDNRB FLNA GDNF HTR3A HTR4
7 endocrine/exocrine gland MP:0005379 10.16 HTR3A KIT OPRM1 RET SLC6A4 VIP
8 immune system MP:0005387 10.11 AQP3 CLCN2 EDNRB FLNA GDNF HTR3A
9 nervous system MP:0003631 10.1 CCK CLCN2 EDNRB FLNA GDNF HTR3A
10 normal MP:0002873 9.81 FLNA KIT OPRM1 PYY RET SLC6A4
11 renal/urinary system MP:0005367 9.61 AQP3 CCK EDNRB GDNF HTR3A KIT
12 respiratory system MP:0005388 9.23 AQP3 EDNRB FLNA HTR4 KIT NALCN

Drugs & Therapeutics for Constipation

Drugs for Constipation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 759)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 465-65-6 5284596
2
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 76-42-6 5284603
3
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 1 42399-41-7 39186
4
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-84-3 187
5
Amitriptyline Approved Phase 4,Not Applicable 50-48-6 2160
6
Cyclobenzaprine Approved Phase 4,Not Applicable 303-53-7 2895
7
Oxybutynin Approved, Investigational Phase 4,Phase 3,Not Applicable 5633-20-5 4634
8
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6 23925
9
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
11
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
12
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
13
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 23994
14
Loperamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53179-11-6 3955
15
Lubiprostone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 136790-76-6 656719
16
Bisacodyl Approved Phase 4,Phase 3,Phase 2,Not Applicable 603-50-9
17
Methylnaltrexone Approved Phase 4,Phase 2,Phase 3,Not Applicable 83387-25-1, 916055-93-1 6603824
18
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 16590-41-3 5360515
19
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
20
Acetaminophen Approved Phase 4,Phase 3,Not Applicable 103-90-2 1983
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
22
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
23
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 138530-94-6, 103577-45-3 9578005
24
Lansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 103577-45-3 3883
25
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 137-58-6 3676
26
Magnesium oxide Approved Phase 4,Phase 2,Not Applicable 1309-48-4 14792
27
Bismuth Subsalicylate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 14882-18-9 53629521
28
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Not Applicable 1309-42-8
29
Naloxegol Approved Phase 4,Phase 3,Phase 2,Phase 1 854601-70-0
30
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
31
Sorbitol Approved Phase 4,Phase 3 50-70-4 5780
32
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 169590-42-5 2662
33
Hydromorphone Approved, Illicit Phase 4,Phase 2,Phase 3 466-99-9 5284570
34
Ibuprofen Approved Phase 4,Phase 1 15687-27-1 3672
35
Ondansetron Approved Phase 4,Phase 1,Not Applicable 99614-02-5 4595
36
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 1 83150-76-9 383414 6400441
37
Magnesium citrate Approved Phase 4 3344-18-1
38
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
39
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
40
Coal tar Approved Phase 4,Phase 3 8007-45-2
41
Propranolol Approved, Investigational Phase 4 525-66-6 4946
42
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
43
Desflurane Approved Phase 4 57041-67-5 42113
44
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
45
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
46
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
47
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
48
Doxazosin Approved Phase 4 74191-85-8 3157
49
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128794-94-5 5281078
50
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 1470)
# Name Status NCT ID Phase Drugs
1 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
2 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
3 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
4 A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy Unknown status NCT01109511 Phase 4 naloxone;oxycodone
5 Pediatrics Anal Fissures Treatment With Polyethylene Glycol Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
6 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
7 A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely Unknown status NCT00889655 Phase 4 Golytely (polyethylene glycol);MiraLax (polyethylene glycol 3350)
8 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
9 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
10 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
11 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
12 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
13 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
14 The Use of Iron Therapy for Patients With Anemia After Surgery Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
15 A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula Unknown status NCT02423330 Phase 4
16 Transversus Abdominis Plane Blocks With Abdominoplasty Unknown status NCT01278264 Phase 4 Ropivacaine 0.25%, 0.5 ml/kg;Ropivacaine 0.25%, 0.5 ml/kg
17 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
18 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
19 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
20 The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
21 Anti-peristaltic Ileo-sigmoid Anastomosis for the Treatment of Slow-transit Constipation:Therapeutic Evaluation Completed NCT02147574 Phase 4
22 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation Completed NCT03054805 Phase 4 Magnesium Oxide;MIYAIRI-BM
23 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
24 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications Completed NCT01096290 Phase 4 lubiprostone;Matched placebo
25 Methylnaltrexone Use for Opioid-induced Postoperative Constipation Completed NCT01773096 Phase 4 Methylnaltrexone;Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
26 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4 placebo;prucalopride
27 Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial Completed NCT01267370 Phase 4
28 Lactobacillus Reuteri DSM 17938 in Functional Constipation Completed NCT01244945 Phase 4
29 Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation Completed NCT02228616 Phase 4 Prucalopride;Polyethylene glycol (PEG);Lactulose
30 Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children Completed NCT01592734 Phase 4 Polyethylene glycol with electrolytes
31 To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Completed NCT03060512 Phase 4 Polyethylene Glycol 3350;Movantik
32 Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Completed NCT00672477 Phase 4 Methylnaltrexone;Placebo
33 The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Completed NCT02726295 Phase 4 E. coli Nissle 1917(Mutaflor®);Placebo
34 Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation Completed NCT00153140 Phase 4 polyethyleneglycol3350
35 Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Completed NCT00672139 Phase 4 Methylnaltrexone bromide
36 An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Completed NCT02590432 Phase 4 Linaclotide 290 micrograms;Linaclotide 145 micrograms;Linaclotide 72 micrograms
37 Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation Completed NCT00603681 Phase 4 Polyethylene glycol 4000;Polyethylene glycol 4000 with electrolytes
38 Lcr35 for Children With Functional Constipation Completed NCT01985867 Phase 4
39 The Effectiveness of Lubiprostone in Constipated Diabetics Completed NCT01170039 Phase 4 Lubiprostone;Placebo
40 Preference of Tegaserod vs. PEG 3350 in Patients With Constipation Completed NCT00171522 Phase 4 Tegaserod and Polyethylene Glycol 3350
41 Dietary Fiber Mixture in Constipated Pediatric Patients Completed NCT01333787 Phase 4
42 Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation Completed NCT00452335 Phase 4 Lubiprostone;Lubiprostone;Lubiprostone
43 Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation Completed NCT00149877 Phase 4 Tegaserod
44 A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). Completed NCT01957046 Phase 4 Laxative
45 Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Completed NCT02839889 Phase 4 Naloxegol;Placebo
46 Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications Completed NCT00153127 Phase 4 polyethyleneglycol3350
47 A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children Completed NCT00319670 Phase 4 MiraLax
48 Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216) Completed NCT00770432 Phase 4 Polyethylene glycol 3350
49 Amitiza in Constipation Associated With PD (Parkinson's Disease) Completed NCT00908076 Phase 4 LUBIPROSTONE
50 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation Completed NCT01460225 Phase 4 lubiprostone

Search NIH Clinical Center for Constipation

Cochrane evidence based reviews: constipation

Genetic Tests for Constipation

Genetic tests related to Constipation:

# Genetic test Affiliating Genes
1 Constipation 29

Anatomical Context for Constipation

MalaCards organs/tissues related to Constipation:

41
Lung, Colon, Breast, Prostate, Kidney, Testes, Liver

Publications for Constipation

Articles related to Constipation:

(show top 50) (show all 936)
# Title Authors Year
1
Effects of a probiotic (SLAB51a8c) on clinical and histologic variables and microbiota of cats with chronic constipation/megacolon: a pilot study. ( 29065705 )
2018
2
Dyssynergic defecation: The not so hidden partner in constipation. ( 29971688 )
2018
3
Stepped-wedge randomised trial of laparoscopic ventral mesh rectopexy in adults with chronic constipation: study protocol for a randomized controlled trial. ( 29402303 )
2018
4
Assessment and management of constipation for patients receiving palliative care in specialist palliative care settings: A systematic review of the literature. ( 29431016 )
2018
5
Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomised controlled trial. ( 29959787 )
2018
6
Efficacy and Safety of Subcutaneous Neostigmine for Ileus, Acute Colonic Pseudo-obstruction, or Refractory Constipation. ( 29359574 )
2018
7
Methylnaltrexone bromide for the treatment of opioid-induced constipation. ( 29979903 )
2018
8
Paediatric<i>Clostridium difficile</i>pseudomembranous colitis: a complication of refractory constipation? ( 29444797 )
2018
9
Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study. ( 29419653 )
2018
10
Erratum: Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]. ( 29950887 )
2018
11
Abdominal radiograph usage trends in the setting of constipation: a 10-year experience. ( 29392367 )
2018
12
Polyethylene glycol maintenance treatment for childhood functional constipation: A Randomized, Placebo-Controlled Trial. ( 29952829 )
2018
13
Infant Feeding Practices and the Effect in Reducing Functional Constipation Six Years Later: A Randomised Field Trial. ( 29927865 )
2018
14
Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. ( 29942351 )
2018
15
Quercetin promotes gastrointestinal motility and mucin secretion in loperamide-induced constipation of SD rats through regulation of the mAChRs downstream signal. ( 29952685 )
2018
16
Long-term outcomes of a Malone antegrade continence enema (MACE) for the treatment of fecal incontinence or constipation in adults. ( 29934702 )
2018
17
Assessing the efficacy of peripherally acting A/-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. ( 29980606 )
2018
18
Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class. ( 29897589 )
2018
19
Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy. ( 29391826 )
2018
20
Randomized phase 3 and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. ( 29912271 )
2018
21
Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. ( 29946799 )
2018
22
Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study. ( 29416370 )
2018
23
The Burden of Opioid-Induced Constipation in Younger Patients with Chronic Noncancer Pain. ( 29420795 )
2018
24
Management of Childhood Functional Constipation: Consensus Practice Guidelines of Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition and Pediatric Gastroenterology Chapter of Indian Academy of Pediatrics. ( 29941697 )
2018
25
Effects of Noninvasive Skin Stimulation with Microcones on Constipation: A Double-Blinded Controlled Study. ( 29410718 )
2018
26
Treatment of poststroke constipation with moxibustion: A case report. ( 29901642 )
2018
27
Acupuncture for patients with chronic functional constipation: A randomized controlled trial. ( 29392784 )
2018
28
Are Senna based laxatives safe when used as long term treatment for constipation in children? ( 29429768 )
2018
29
The authors respond: The ED diagnostic workup of constipation in children. ( 29395764 )
2018
30
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. ( 29406801 )
2018
31
Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide. ( 29979299 )
2018
32
Aetiological spectrum, clinical differentiation and efficacy of polyethylene glycol over lactulose in children with constipation: Experience of 316 cases. ( 29943871 )
2018
33
Clinical practice guidelines from the French National Society of Coloproctology in treating chronic constipation. ( 29406436 )
2018
34
Long-term follow-up of the effects of fecal microbiota transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow transit constipation. ( 29441452 )
2018
35
The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. ( 29684865 )
2018
36
Constipation in children: NICE guidance in practice in two emergency departments. ( 29395754 )
2018
37
Subtotal colonic bypass plus colostomy with antiperistaltic cecoproctostomy for the treatment of slow transit constipation in an aged population: A retrospective control study. ( 29930470 )
2018
38
Efficacy and safety of acupuncture for functional constipation: a randomised, sham-controlled pilot trial. ( 29903020 )
2018
39
Probiotics decrease depressive behaviors induced by constipation via activating the AKT signaling pathway. ( 29948655 )
2018
40
Antenatal Bartter syndrome presenting with vomiting and constipation mimicking subacute intestinal obstruction in a 20-day-old neonate. ( 29141924 )
2017
41
Physical activity may decrease the likelihood of children developing constipation. ( 28898506 )
2017
42
Enuresis and Constipation in a 12-Year-Old. ( 28952347 )
2017
43
Reliability and validity of the Bowel Function Index for evaluating opioid-induced constipation: translation, cultural adaptation and validation of the Portuguese version (BFI-P). ( 27981871 )
2017
44
Supporting patients in reducing postoperative constipation: fundamental nursing care - a quasi-experimental study. ( 28881476 )
2017
45
Physiologic Management of Chronic Constipation: Let's FEED It. ( 28948409 )
2017
46
Osteopathic Manipulative Treatment Limits Chronic Constipation in a Child with Pitt-Hopkins Syndrome. ( 28251008 )
2017
47
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. ( 28083815 )
2017
48
Mashiningan Improves Opioid-Induced Constipation in Rats by Activating Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel. ( 28465373 )
2017
49
Effect Of Prucalopride on Intestinal Gas Tolerance in Patients With Functional Bowel Disorders and Constipation. ( 28090679 )
2017
50
A case of sulfhemoglobinemia in a child with chronic constipation. ( 28348950 )
2017

Variations for Constipation

ClinVar genetic disease variations for Constipation:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
2 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh38 Chromosome 10, 43121968: 43121968
3 ARID1B NM_020732.3(ARID1B): c.4110G> A (p.Pro1370=) single nucleotide variant Conflicting interpretations of pathogenicity rs797045277 GRCh37 Chromosome 6, 157520041: 157520041
4 ARID1B NM_020732.3(ARID1B): c.4110G> A (p.Pro1370=) single nucleotide variant Conflicting interpretations of pathogenicity rs797045277 GRCh38 Chromosome 6, 157198907: 157198907
5 Translocation Likely pathogenic
6 46;XX;t(7;13)(p13;q34)dn Translocation Pathogenic
7 46;XY;t(9;11)(q34;p11.2)dn Translocation Pathogenic
8 46;XX;t(19;21)(q13.3;q22.3)dn Translocation Pathogenic
9 PPOX NM_000309.4(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 GRCh37 Chromosome 1, 161140885: 161140885
10 PPOX NM_000309.4(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 GRCh38 Chromosome 1, 161171095: 161171095

Expression for Constipation

Search GEO for disease gene expression data for Constipation.

Pathways for Constipation

GO Terms for Constipation

Cellular components related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 CLCN2 EDNRB HTR3A HTR4 KIT OPRM1
2 membrane raft GO:0045121 9.62 EDNRB OPRM1 RET SLC6A4
3 axon GO:0030424 9.35 CCK HTR3A OPRM1 RET TAC1
4 neuronal cell body GO:0043025 9.1 CCK FLNA HTR3A RET SST TAC1
5 plasma membrane GO:0005886 10.07 AQP3 CLCN2 EDNRB FLNA HTR3A HTR4

Biological processes related to Constipation according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.95 EDNRB FLNA GDNF KIT RET
2 positive regulation of cell proliferation GO:0008284 9.92 CCK EDNRB GDNF KIT VIP
3 response to drug GO:0042493 9.88 PPOX RET SLC6A4 SST
4 chemical synaptic transmission GO:0007268 9.8 HTR3A HTR4 OPRM1 SST TAC1
5 neuropeptide signaling pathway GO:0007218 9.73 OPRM1 PYY TAC1
6 regulation of signaling receptor activity GO:0010469 9.73 CCK GDNF MLN PYY SST VIP
7 sensory perception of pain GO:0019233 9.63 EDNRB OPRM1 TAC1
8 neural crest cell migration GO:0001755 9.61 EDNRB GDNF RET
9 mRNA stabilization GO:0048255 9.59 GDNF VIP
10 melanocyte differentiation GO:0030318 9.58 EDNRB KIT
11 vasoconstriction GO:0042310 9.57 EDNRB SLC6A4
12 positive regulation of renal sodium excretion GO:0035815 9.54 EDNRB TAC1
13 regulation of sensory perception of pain GO:0051930 9.54 CCK EDNRB OPRM1
14 developmental pigmentation GO:0048066 9.51 EDNRB KIT
15 regulation of appetite GO:0032098 9.49 HTR4 PYY
16 response to pain GO:0048265 9.33 EDNRB RET TAC1
17 posterior midgut development GO:0007497 9.32 EDNRB RET
18 G-protein coupled receptor signaling pathway GO:0007186 9.32 CCK EDNRB HTR4 MLN MLNR OPRM1
19 enteric nervous system development GO:0048484 9.13 EDNRB GDNF RET
20 signal transduction GO:0007165 10.13 CCK EDNRB GDNF HTR3A HTR4 KIT

Molecular functions related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 GDNF KIT RET
2 neuropeptide hormone activity GO:0005184 9.13 CCK PYY VIP
3 hormone activity GO:0005179 9.02 CCK MLN PYY SST VIP

Sources for Constipation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....